On September 2, 2022, FDA Commissioner Robert M. Califf, M.D. and CBER Director Peter Marks, M.D., conducted a virtual meeting with key stakeholders on, to discuss FDA’s August 31, 2022, decision to amend the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine. The amended EUA authorizes bivalent formulations of the vaccines for use as a single booster dose at least two months following primary or booster vaccination.
